Cha De Bugre - Ruxolitinib Interaction Details

Interaction Details

There were no interactions found between Ruxolitinib and Cha De Bugre. This does not mean the potential for an interaction does not exist, however. There is often a lack of studies and data surrounding traditional medicine, especially concerning drug interactions, so it is important to always consult your provider before making any changes to your medication regimen.

Still looking for more information about combining Ruxolitinib and Cha De Bugre? Ask Dr. Brian Staiger about it by contacting him directly.

Ruxolitinib Overview

Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). It is also used to treat polycythemia vera (PV; a slow growing cancer of the blood in which the bone marrow makes too many red blood cells) in people who were not able to be treated successfully with hydroxyurea. Ruxolitinib is also used to treat acute graft versus host disease (aGVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow] that usually develops within the first months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with steroid medications. It is also used to treat chronic GVHD (cGVHD; a complication of HSCT that usually develops at least 3 months after HSCT) in adults and children 12 years of age and older who were treated unsuccessfully with 1 or 2 other treatments. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.

See More Information Regarding Ruxolitinib

Cha De Bugre - More Interactions

Cha De Bugre interacts with 0 drugs

Unknown 2750 Interactions

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.

Major	The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur.
Moderate	Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur.
Minor	Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction.
Unknown	No interactions have been reported or no interaction data is currently available.